Adam Keeney
Fortuna: 1 M $ al 31/05/2026
Fortuna: 1 M $ al 31/05/2026
Adam Keeney is Executive VP & Head-Corporate Development at Biogen, Inc. since 2023.
Formerly, Dr. Keeney was President, Chief Executive Officer & Director at NodThera Ltd. from 2018 to 2022.
Dr. Keeney completed undergraduate studies at the University of Leeds and earned a doctorate from The University of Nottingham.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
BIOGEN INC. 0 % | 01/05/2026 | 6.365 ( 0 % ) | 1 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 17/04/2023 |
| Empresas | Cargo | Fin |
|---|---|---|
NodThera Ltd.
NodThera Ltd. BiotechnologyHealth Technology Operates biotechnology company which discovers and develops new treatments for diseases driven by chronic inflammation | Director Ejecutivo | 01/01/2022 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Biogen, Inc.
Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
University of Leeds
University of Leeds Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Nottingham
The University of Nottingham Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NodThera Ltd.
NodThera Ltd. BiotechnologyHealth Technology Operates biotechnology company which discovers and develops new treatments for diseases driven by chronic inflammation | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.